What is the current IDH1 Antibody market size?

The IDH1 Antibody market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the IDH1 Antibody market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the IDH1 Antibody market?

Increasing demand for targeted therapies drives the IDH1 Antibody market.

What are the challenges facing the IDH1 Antibody market?

High development costs and regulatory hurdles challenge the IDH1 Antibody market.

Which regions lead the IDH1 Antibody market?

North America and Europe are the leading regions in the IDH1 Antibody market.

Who are the top companies in the IDH1 Antibody market?

Leading companies include Agilent and Abcam in the IDH1 Antibody market.

What future opportunities exist in the IDH1 Antibody market?

Emerging applications in diagnostics and research create future opportunities.

How does technology impact the IDH1 Antibody market?

Advances in antibody development technology enhance the IDH1 Antibody market.

What is the regulatory landscape for the IDH1 Antibody market?

Stringent regulations govern the IDH1 Antibody market, ensuring safety and efficacy.

What is the future outlook for the IDH1 Antibody market?

The future outlook is positive, driven by increasing demand and innovation.

IDH1 Antibody Market 2026: Primary Research + Expert Analysis

IDH1 Antibody by Type (Monoclonal, Polyclonal, World IDH1 Antibody Production), by Application (Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others, World IDH1 Antibody Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

IDH1 Antibody Market Size | CAGR 10.2 Forecast 2033

IDH1 Antibody Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

IDH1 Antibody Market Overview

The IDH1 Antibody market refers to the global market for antibodies targeting Isocitrate Dehydrogenase 1 (IDH1), an enzyme involved in cellular metabolism. As a key area of focus in the cancer research and immunotherapy fields, the IDH1 Antibody market size is estimated to be around $1.3 billion. The growth outlook for the IDH1 Antibody market is promising, with a market forecast indicating significant expansion during the forecast period of 2026-2033. This industry expansion is driven by increasing demand for targeted therapies and advancements in biotechnology. The scope of the IDH1 Antibody market encompasses various types of antibodies, applications, and end-users, including research institutions, pharmaceutical companies, and hospitals.

Loading chart…

The IDH1 Antibody market is expected to grow at a CAGR of around 10% during the forecast period, driven by macro drivers such as increasing cancer prevalence and advancements in genetic engineering. Key forces shaping the industry include technology shifts towards personalized medicine, regulations supporting biotechnology innovation, and changing consumer behavior towards targeted therapies. The largest region in the IDH1 Antibody market is North America, while the fastest-growing region is Asia-Pacific. Overall, the IDH1 Antibody market is poised for significant growth, driven by increasing demand for effective and targeted therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; GeneTex; Abcam; BosterBio; Proteintech Group; Abnova Corporation; Novus Biologicals; NSJ Bioreagents; LifeSpan BioSciences; Abeomics; ProSci; QED Bioscience; Cell Signaling Technology; RayBiotech; EpiGentek; Enzo Life Sciences; OriGene Technologies; Jingjie PTM BioLab; Beijing Solarbio; Biobyt
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The IDH1 Antibody market is poised for significant growth, driven by increasing demand for targeted therapies and advancements in research and development. The IDH1 Antibody market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR, are expected to fuel the development of novel IDH1 Antibody treatments, driving market growth

Rising prevalence of cancers with IDH1 mutations, such as acute myeloid leukemia, is anticipated to increase demand for IDH1 Antibody-based therapies

Restraints2 items

High development costs and regulatory hurdles may hinder the growth of the IDH1 Antibody market, as companies may be deterred from investing in research and development

Intense competition among existing treatments and therapies may limit the market share of new IDH1 Antibody products, making it challenging for companies to penetrate the market

Opportunities2 items

Emerging markets, particularly in Asia-Pacific regions, offer significant opportunities for IDH1 Antibody market expansion, driven by increasing healthcare spending and growing demand for innovative treatments

The development of combination therapies using IDH1 Antibody and other treatments may provide new opportunities for market growth, as companies explore innovative approaches to cancer treatment

Challenges2 items

Ensuring supply chain resilience and managing manufacturing costs will be crucial challenges for companies operating in the IDH1 Antibody market, as they strive to maintain profitability

Addressing reimbursement and pricing pressures will be essential for companies to ensure the long-term sustainability of their IDH1 Antibody products in a competitive market

Market Segmentation

Loading chart…

The IDH1 Antibody market can be segmented by Type, which refers to the various forms of IDH1 antibodies available. This segmentation is crucial in understanding the IDH1 Antibody market size, as different types of antibodies have distinct applications and demand. The type segment includes monoclonal and polyclonal antibodies, each with its own set of characteristics and uses.

The Application segment is another critical aspect of IDH1 Antibody segmentation. This segment categorizes the market based on the various uses of IDH1 antibodies, such as research and development, diagnostics, and therapeutics. Understanding the application segment is essential for determining the IDH1 Antibody market size, as it highlights the areas where IDH1 antibodies are in high demand.

IDH1 Antibody Segmentation Breakdown12 items

Type

Monoclonal

Polyclonal

World IDH1 Antibody Production

Application

Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

World IDH1 Antibody Production

Regional Insights

Loading chart…

The IDH1 Antibody market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced technologies, favorable policies, and significant investments in the healthcare sector.

Key drivers for North America include a mature ecosystem, high infrastructure development, and a large patient pool. Europe's growth is driven by demographics, with an aging population and increasing demand for healthcare services. Asia Pacific's growth is fueled by government initiatives, rising income levels, and expanding healthcare access. Latin America's growth is driven by increasing awareness and improving infrastructure, while the Middle East & Africa region is driven by growing demand and expanding healthcare services.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by emerging markets and increasing adoption of IDH1 Antibody treatments. North America and Europe will maintain their market share, while Latin America and the Middle East & Africa will experience steady growth. The IDH1 Antibody market growth will be influenced by factors such as regulatory frameworks, reimbursement policies, and competition among market players.

Competitive Landscape

The IDH1 Antibody market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. The IDH1 Antibody competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and strategic partnerships, while local companies emphasize regional expansion and cost competitiveness.

Companies in the IDH1 Antibody market employ various strategies to differentiate themselves, including technology, service model, channel strength, customization, and cost advantages. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies focus on strategic initiatives like M&A, partnerships, product launches, and R&D. The following companies exemplify these strategies:

Merck: regional expansion

Abcam: premium pricing

GeneTex: innovation pipeline

Proteintech Group: local manufacturing

Abnova Corporation: OEM tie-ups

Cell Signaling Technology: vertical integration

Key IDH1 Antibody Companies20 items

Merck

GeneTex

Abcam

BosterBio

Proteintech Group

Abnova Corporation

Novus Biologicals

NSJ Bioreagents

LifeSpan BioSciences

Abeomics

ProSci

QED Bioscience

Cell Signaling Technology

RayBiotech

EpiGentek

Enzo Life Sciences

OriGene Technologies

Jingjie PTM BioLab

Beijing Solarbio

Biobyt

Market Ecosystem

The IDH1 Antibody ecosystem spans multiple stages, from upstream technology providers and suppliers to midstream integrators and downstream channels, ultimately reaching end users. Value is created and captured as innovation and expertise are transferred across these stages, from research and development to commercialization and distribution. Understanding the IDH1 Antibody ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material/component suppliers — provide critical reagents

Technology providers — develop innovative detection methods

OEMs / manufacturers — produce high-quality antibodies

Distributors / channel partners — ensure widespread availability

Service providers / after-sales — offer technical support and maintenance

End users / buyers — utilize antibodies in research and diagnostics

Regulators/standards bodies — establish and enforce quality standards

The flow of value within the IDH1 Antibody ecosystem can be influenced by various control points, such as regulatory approvals and standards set by governing bodies. Dependency risks, including input constraints and approval timelines, can also impact the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can affect how participants interact and create value. The ecosystem's dynamics can differ by region due to variations in regulatory frameworks, market demand, and the presence of local stakeholders.

Recent Industry Insights

The IDH1 Antibody industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed between key players to enhance research and development capabilities, driving innovation in the field. Recent mergers and acquisitions have also led to the expansion of product portfolios, enabling companies to cater to a broader range of applications. Furthermore, several product and technology launches have been observed, focusing on improved sensitivity and specificity of IDH1 Antibody-based assays.

Additionally, regulatory changes have influenced the IDH1 Antibody industry trends, with an increased emphasis on obtaining approvals for diagnostic and therapeutic applications. A shift in consumer and enterprise trends has also been observed, with a growing demand for personalized medicine and targeted therapies. Funding rounds and expansions have been secured by several companies, allowing them to invest in research and development, and scale up their operations to meet the rising demand for IDH1 Antibody-based products.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the IDH1 Antibody market outlook. The market attractiveness is moderate, driven by growing demand for targeted therapies in oncology. Competitive intensity is high, with several key players vying for market share. The long-term outlook is positive, with increasing research and development activities focused on innovative treatments. The innovation landscape is evolving rapidly, with advancements in personalized medicine and biomarker-based therapies. Demand-supply balance is expected to be stable, with manufacturers ramping up production to meet growing demand. Key risk factors include regulatory challenges and intellectual property disputes.

12 items

1. Executive Summary

2. IDH1 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global IDH1 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global IDH1 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global IDH1 Antibody Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global IDH1 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global IDH1 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global IDH1 Antibody Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global IDH1 Antibody Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global IDH1 Antibody Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global IDH1 Antibody Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global IDH1 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global IDH1 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global IDH1 Antibody Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global IDH1 Antibody Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global IDH1 Antibody Market Competition by Key Manufacturers

9.1. Global IDH1 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global IDH1 Antibody: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GeneTex

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Abcam

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. BosterBio

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Proteintech Group

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Abnova Corporation

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Novus Biologicals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. NSJ Bioreagents

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. LifeSpan BioSciences

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Abeomics

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. ProSci

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. QED Bioscience

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Cell Signaling Technology

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. RayBiotech

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. EpiGentek

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Enzo Life Sciences

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. OriGene Technologies

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Jingjie PTM BioLab

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Beijing Solarbio

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Biobyt

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global IDH1 Antibody Market

Figure 4: Global IDH1 Antibody Market: Drivers

Figure 5: Global IDH1 Antibody Market: Challenges

Figure 6: Global IDH1 Antibody Market: Trends

Figure 7: Global IDH1 Antibody Market: Opportunity

Figure 8: Global IDH1 Antibody Market: Restraint

Figure 9: Global IDH1 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global IDH1 Antibody Market Value (USD Million) By Region

Figure 19: Global IDH1 Antibody Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global IDH1 Antibody Market Value (USD Million) By Region

Figure 27: Global IDH1 Antibody Market Share (%) By: Regions (2032)

Figure 28: Global IDH1 Antibody Market Volume (K) By Region

Figure 29: Global IDH1 Antibody Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global IDH1 Antibody Market Value (USD Million) By Region

Figure 37: Global IDH1 Antibody Market Share (%) By: Regions (2032)

Figure 38: Global IDH1 Antibody Market Volume (K) By Region

Figure 39: Global IDH1 Antibody Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

135 items

Table 1: Market Segmentation Analysis

Table 2: Global IDH1 Antibody Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global IDH1 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global IDH1 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global IDH1 Antibody Market Value (USD Million) By Region

Table 14: Global IDH1 Antibody Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global IDH1 Antibody Market Volume (K) By Region

Table 31: Global IDH1 Antibody Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global IDH1 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global IDH1 Antibody Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global IDH1 Antibody Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck Basic Information And Sales Area

Table 52: Merck. Products Portfolio

Table 53: GeneTex Basic Information And Sales Area

Table 54: GeneTex. Products Portfolio

Table 55: Abcam Basic Information And Sales Area

Table 56: Abcam. Products Portfolio

Table 57: BosterBio Basic Information And Sales Area

Table 58: BosterBio. Products Portfolio

Table 59: Proteintech Group Basic Information And Sales Area

Table 60: Proteintech Group. Products Portfolio

Table 61: Abnova Corporation Basic Information And Sales Area

Table 62: Abnova Corporation. Products Portfolio

Table 63: Novus Biologicals Basic Information And Sales Area

Table 64: Novus Biologicals. Products Portfolio

Table 65: NSJ Bioreagents Basic Information And Sales Area

Table 66: NSJ Bioreagents. Products Portfolio

Table 67: LifeSpan BioSciences Basic Information And Sales Area

Table 68: LifeSpan BioSciences. Products Portfolio

Table 69: Abeomics Basic Information And Sales Area

Table 70: Abeomics. Products Portfolio

Table 71: ProSci Basic Information And Sales Area

Table 72: ProSci. Products Portfolio

Table 73: QED Bioscience Basic Information And Sales Area

Table 74: QED Bioscience. Products Portfolio

Table 75: Cell Signaling Technology Basic Information And Sales Area

Table 76: Cell Signaling Technology. Products Portfolio

Table 77: RayBiotech Basic Information And Sales Area

Table 78: RayBiotech. Products Portfolio

Table 79: EpiGentek Basic Information And Sales Area

Table 80: EpiGentek. Products Portfolio

Table 81: Enzo Life Sciences Basic Information And Sales Area

Table 82: Enzo Life Sciences. Products Portfolio

Table 83: OriGene Technologies Basic Information And Sales Area

Table 84: OriGene Technologies. Products Portfolio

Table 85: Jingjie PTM BioLab Basic Information And Sales Area

Table 86: Jingjie PTM BioLab. Products Portfolio

Table 87: Beijing Solarbio Basic Information And Sales Area

Table 88: Beijing Solarbio. Products Portfolio

Table 89: Biobyt Basic Information And Sales Area

Table 90: Biobyt. Products Portfolio

Table 91: Global Market Value (USD Million) (2025-2032) By Type

Table 92: Global Market Share (%) By Type (2032)

Table 93: Global Market Value (USD Million) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Market Volume (K) (2025-2032) By Type

Table 96: Global Market Share (%) By Type (2032)

Table 97: Global Market Volume (K) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global IDH1 Antibody Market Value (USD Million) By Region

Table 100: Global IDH1 Antibody Market Share (%) By Region (2025-2032)

Table 101: North America Market Value (USD Million) (2025-2032) By Country

Table 102: North America Market Value (USD Million) (2025-2032) By Type

Table 103: North America Market Value (USD Million) (2025-2032) By Application

Table 104: Europe Market Value (USD Million) (2025-2032) By Country

Table 105: Europe Market Value (USD Million) (2025-2032) By Type

Table 106: Europe Market Value (USD Million) (2025-2032) By Application

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 108: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 110: South America Market Value (USD Million) (2025-2032) By Country

Table 111: South America Market Value (USD Million) (2025-2032) By Type

Table 112: South America Market Value (USD Million) (2025-2032) By Application

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 114: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 116: Global IDH1 Antibody Market Volume (K) By Region

Table 117: Global IDH1 Antibody Market Share (%) By Region (2025-2032)

Table 118: North America Market Volume (K) (2025-2032) By Country

Table 119: North America Market Volume (K) (2025-2032) By Type

Table 120: North America Market Volume (K) (2025-2032) By Application

Table 121: Europe Market Volume (K) (2025-2032) By Country

Table 122: Europe Market Volume (K) (2025-2032) By Type

Table 123: Europe Market Volume (K) (2025-2032) By Application

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 125: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 127: South America Market Volume (K) (2025-2032) By Country

Table 128: South America Market Volume (K) (2025-2032) By Type

Table 129: South America Market Volume (K) (2025-2032) By Application

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 131: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 133: Research Programs/Design For This Report

Table 134: Key Data Information From Secondary Sources

Table 135: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

IDH1 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; GeneTex; Abcam; BosterBio; Proteintech Group; Abnova Corporation; Novus Biologicals; NSJ Bioreagents; LifeSpan BioSciences; Abeomics; ProSci; QED Bioscience; Cell Signaling Technology; RayBiotech; EpiGentek; Enzo Life Sciences; OriGene Technologies; Jingjie PTM BioLab; Beijing Solarbio; Biobyt
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options